Nevirapine resistance in women and infants after first versus repeated use of single-dose nevirapine for prevention of HIV-1 vertical transmission

Tamara S. Flys, Michelle S. McConnell, Flavia Matovu, Jessica D. Church, Danstan Bagenda, Leila Khaki, Paul Bakaki, Michael C. Thigpen, Chineta Eure, Mary Glenn Fowler, Susan H. Eshleman

Research output: Contribution to journalArticle

Abstract

Single-dose (SD) nevirapine (NVP) significantly reduces mother-to-child transmission of human immunodeficiency virus (HIV). We analyzed NVP resistance after receipt of SDNVP in 57 previously SD NVP-naive women, in 34 SD NVP-experienced women, and in 17 HIV-infected infants. The proportion of women infected with variants with resistance mutations, the types of mutations detected, and the frequency and level of K103N were similar in the two groups ofwomenat 6 weeks and 6 months post partum. NVP resistance was detected in a similar proportion of infants born to SD NVP-naive versus SD NVP-experienced women. Repeated use of SD NVP to prevent HIV transmission does not appear to influence NVP resistance.

Original languageEnglish (US)
Pages (from-to)465-469
Number of pages5
JournalJournal of Infectious Diseases
Volume198
Issue number4
DOIs
StatePublished - Aug 15 2008

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Nevirapine resistance in women and infants after first versus repeated use of single-dose nevirapine for prevention of HIV-1 vertical transmission'. Together they form a unique fingerprint.

  • Cite this